New to Insight Pharma Reports is: MicroRNA: An Insight to miRNA-Based Microarrays, Diagnostics and Therapeutics. This report covers the specifics of microRNA (miRNA) as it is a relatively new space in heavy pursuit of research due to its versatility and stability, properties that are unique to miRNAs compared to other RNA components. miRNA's non-coding nature and ability to affect genetic expression make it a novel candidate for use as a biomarker for a variety of diseases. This prompted the pursuit of miRNA-based microarrays and diagnostics for the advancement in therapeutic development. Furthermore there are a number of academic laboratories not only validating miRNAs, but also identifying them in a number of diseases and examining their molecular actions in the presence of other molecules. This report is broken up into several parts, highlighting miRNA in several areas of research.
After covering background information, the second and third parts of this report expand upon several microarrays and diagnostics for specific analysis and therapeutic development. Several companies featured in this section include:
• Rosetta Genomics
Chapters within these sections feature company backgrounds and highlight proprietary technologies and platforms. Additionally, several advantages and limitations are also discussed. More significantly, these chapters are accompanied by interviews with company representatives, exclusively conducted for this report.
The fourth part of this report explores the academic, research and community perspectives. Although not developing diagnostics per se, academia is diligently investigating several aspects of miRNAs including their molecular properties for use as biomarkers for neurodegenerative diseases, diabetes, and even cancer. Universities and research institutes included in this area are:
• Stony Brook University School of Medicine
• Grand Valley State University
• Van Andel Research Institute
Also included in these sections are interviews with experts in leading research from these universities. From a community perspective, Dr. Argyropoulos, a Medical Affairs Consultant, provides insight to the rapidly growing space and rising opportunities.
Finally, the report concludes with an in depth analysis of survey results. With 152 researchers, these results provide an overall perspective of the research community, capturing a number of miRNA applications, challenges afloat in the industry, and miRNA mechanisms of study.